B. Metzler seel. Sohn & Co. AG Has $10.83 Million Holdings in IDEXX Laboratories, Inc. $IDXX

B. Metzler seel. Sohn & Co. AG trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 20.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,947 shares of the company’s stock after selling 4,388 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in IDEXX Laboratories were worth $10,827,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. J.Safra Asset Management Corp bought a new position in IDEXX Laboratories during the third quarter worth $31,000. Armstrong Advisory Group Inc. boosted its holdings in IDEXX Laboratories by 55.9% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after purchasing an additional 19 shares during the period. Salomon & Ludwin LLC acquired a new stake in IDEXX Laboratories in the 3rd quarter worth $35,000. Greykasell Wealth Strategies Inc. acquired a new stake in IDEXX Laboratories in the 3rd quarter worth $35,000. Finally, WealthCollab LLC bought a new position in shares of IDEXX Laboratories during the 2nd quarter worth about $30,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. BTIG Research decreased their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. UBS Group lowered their price target on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 3rd. Barclays reduced their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Finally, Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Seven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $783.33.

Insider Activity at IDEXX Laboratories

In other news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total value of $15,338,011.30. Following the sale, the chief executive officer directly owned 83,606 shares in the company, valued at approximately $54,975,125.30. This represents a 21.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Sophie V. Vandebroek sold 1,464 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the completion of the transaction, the director directly owned 648 shares of the company’s stock, valued at approximately $407,345.76. The trade was a 69.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 45,957 shares of company stock valued at $29,862,109. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $608.41 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The company has a 50-day moving average of $666.94 and a 200-day moving average of $668.42. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98. The company has a market capitalization of $48.44 billion, a price-to-earnings ratio of 46.55, a PEG ratio of 3.70 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the firm earned $2.53 EPS. The business’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.